Comparative ability of digoxin and an aminosugar cardiac glycoside to bind to and inhibit Na+,K+-adenosine triphosphatase. Effect of potassium

Emel Songu-Mize, Janet L. Gunter, Robert William Caldwell

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We compared the abilities of digoxin and aminogalactose digitoxigenin (ASI-222) to bind to, or inhibit, purified dog heart Na+,K+-ATPase in the presence of 1, 10, or 80 mM potassium chloride. Changing the potassium concentration from 1 to 10 mM increased the dose producing 50% inhibition of enzyme activity (IC50) by 9- and 2.5-fold for digoxin and ASI-222 respectively. Raising the potassium concentration to 80 mM increased the IC50 for digoxin 3-fold but did not alter significantly the IC50 for ASI-222. Equilibrium binding studies showed that this enzyme exhibited a single class of specific binding sites for both digoxin and ASI-222. Raising the potassium concentration did not affect the maximum number of binding sites (Bmax) but increased the apparent dissociation constant (KD) for digoxin. Potassium differentially affected the affinity and number of binding sites for ASI-222; raising the potassium concentration from 1 to 10 mM did not affect the Bmax or the KD, but raising it to 80 mM increased both. The effect of i.v. infusion of potassium chloride upon cardiac arrhythmias produced by i.v. infusion of digoxin or ASI-222 in anesthetized dogs was also determined. Infusion of potassium chloride reversed the cardiac arrhythmias due to digoxin to normal rhythm, but not those due to ASI-222. In conclusion, the interaction of digoxin and the polar digitals agent, ASI-222, with dog heart Na+,K+-ATPase was differentially affected by potassium. These agents also produced cardiac arrhythmias, which were differentially affected by potassium.

Original languageEnglish (US)
Pages (from-to)3689-3695
Number of pages7
JournalBiochemical Pharmacology
Volume38
Issue number21
DOIs
StatePublished - Nov 1 1989
Externally publishedYes

Fingerprint

Cardiac Glycosides
Digoxin
Adenosine Triphosphatases
Potassium
Potassium Chloride
Inhibitory Concentration 50
Cardiac Arrhythmias
Binding Sites
Dogs
Digitoxigenin
Enzyme inhibition
ASI-222
Enzyme activity
Enzymes

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Comparative ability of digoxin and an aminosugar cardiac glycoside to bind to and inhibit Na+,K+-adenosine triphosphatase. Effect of potassium. / Songu-Mize, Emel; Gunter, Janet L.; Caldwell, Robert William.

In: Biochemical Pharmacology, Vol. 38, No. 21, 01.11.1989, p. 3689-3695.

Research output: Contribution to journalArticle

@article{46bed85be2a241e595725c10201c1d4f,
title = "Comparative ability of digoxin and an aminosugar cardiac glycoside to bind to and inhibit Na+,K+-adenosine triphosphatase. Effect of potassium",
abstract = "We compared the abilities of digoxin and aminogalactose digitoxigenin (ASI-222) to bind to, or inhibit, purified dog heart Na+,K+-ATPase in the presence of 1, 10, or 80 mM potassium chloride. Changing the potassium concentration from 1 to 10 mM increased the dose producing 50{\%} inhibition of enzyme activity (IC50) by 9- and 2.5-fold for digoxin and ASI-222 respectively. Raising the potassium concentration to 80 mM increased the IC50 for digoxin 3-fold but did not alter significantly the IC50 for ASI-222. Equilibrium binding studies showed that this enzyme exhibited a single class of specific binding sites for both digoxin and ASI-222. Raising the potassium concentration did not affect the maximum number of binding sites (Bmax) but increased the apparent dissociation constant (KD) for digoxin. Potassium differentially affected the affinity and number of binding sites for ASI-222; raising the potassium concentration from 1 to 10 mM did not affect the Bmax or the KD, but raising it to 80 mM increased both. The effect of i.v. infusion of potassium chloride upon cardiac arrhythmias produced by i.v. infusion of digoxin or ASI-222 in anesthetized dogs was also determined. Infusion of potassium chloride reversed the cardiac arrhythmias due to digoxin to normal rhythm, but not those due to ASI-222. In conclusion, the interaction of digoxin and the polar digitals agent, ASI-222, with dog heart Na+,K+-ATPase was differentially affected by potassium. These agents also produced cardiac arrhythmias, which were differentially affected by potassium.",
author = "Emel Songu-Mize and Gunter, {Janet L.} and Caldwell, {Robert William}",
year = "1989",
month = "11",
day = "1",
doi = "10.1016/0006-2952(89)90574-1",
language = "English (US)",
volume = "38",
pages = "3689--3695",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "21",

}

TY - JOUR

T1 - Comparative ability of digoxin and an aminosugar cardiac glycoside to bind to and inhibit Na+,K+-adenosine triphosphatase. Effect of potassium

AU - Songu-Mize, Emel

AU - Gunter, Janet L.

AU - Caldwell, Robert William

PY - 1989/11/1

Y1 - 1989/11/1

N2 - We compared the abilities of digoxin and aminogalactose digitoxigenin (ASI-222) to bind to, or inhibit, purified dog heart Na+,K+-ATPase in the presence of 1, 10, or 80 mM potassium chloride. Changing the potassium concentration from 1 to 10 mM increased the dose producing 50% inhibition of enzyme activity (IC50) by 9- and 2.5-fold for digoxin and ASI-222 respectively. Raising the potassium concentration to 80 mM increased the IC50 for digoxin 3-fold but did not alter significantly the IC50 for ASI-222. Equilibrium binding studies showed that this enzyme exhibited a single class of specific binding sites for both digoxin and ASI-222. Raising the potassium concentration did not affect the maximum number of binding sites (Bmax) but increased the apparent dissociation constant (KD) for digoxin. Potassium differentially affected the affinity and number of binding sites for ASI-222; raising the potassium concentration from 1 to 10 mM did not affect the Bmax or the KD, but raising it to 80 mM increased both. The effect of i.v. infusion of potassium chloride upon cardiac arrhythmias produced by i.v. infusion of digoxin or ASI-222 in anesthetized dogs was also determined. Infusion of potassium chloride reversed the cardiac arrhythmias due to digoxin to normal rhythm, but not those due to ASI-222. In conclusion, the interaction of digoxin and the polar digitals agent, ASI-222, with dog heart Na+,K+-ATPase was differentially affected by potassium. These agents also produced cardiac arrhythmias, which were differentially affected by potassium.

AB - We compared the abilities of digoxin and aminogalactose digitoxigenin (ASI-222) to bind to, or inhibit, purified dog heart Na+,K+-ATPase in the presence of 1, 10, or 80 mM potassium chloride. Changing the potassium concentration from 1 to 10 mM increased the dose producing 50% inhibition of enzyme activity (IC50) by 9- and 2.5-fold for digoxin and ASI-222 respectively. Raising the potassium concentration to 80 mM increased the IC50 for digoxin 3-fold but did not alter significantly the IC50 for ASI-222. Equilibrium binding studies showed that this enzyme exhibited a single class of specific binding sites for both digoxin and ASI-222. Raising the potassium concentration did not affect the maximum number of binding sites (Bmax) but increased the apparent dissociation constant (KD) for digoxin. Potassium differentially affected the affinity and number of binding sites for ASI-222; raising the potassium concentration from 1 to 10 mM did not affect the Bmax or the KD, but raising it to 80 mM increased both. The effect of i.v. infusion of potassium chloride upon cardiac arrhythmias produced by i.v. infusion of digoxin or ASI-222 in anesthetized dogs was also determined. Infusion of potassium chloride reversed the cardiac arrhythmias due to digoxin to normal rhythm, but not those due to ASI-222. In conclusion, the interaction of digoxin and the polar digitals agent, ASI-222, with dog heart Na+,K+-ATPase was differentially affected by potassium. These agents also produced cardiac arrhythmias, which were differentially affected by potassium.

UR - http://www.scopus.com/inward/record.url?scp=0024449595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024449595&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(89)90574-1

DO - 10.1016/0006-2952(89)90574-1

M3 - Article

VL - 38

SP - 3689

EP - 3695

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 21

ER -